Answers are grounded in this paper and cite their sources.
Literature review summarizes SMARCA4-directed therapies in oncology clinical trials, indicating their potential role.
-mutated cancer. Currently, all published clinical trials of SMARCA4-directed therapies are for orally bioavailable small-molecule inhibitors. Clinical trials without results include small-molecule inhibitors, monoclonal antibodies, and a bifunctional MabPair product. The aim of this literature review was to summarize the current SMARCA4-directed therapies in oncology clinical trials.
No takes yet. Share an insight, caveat, or question.
HENDEE et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: